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Summary Resistance of tumour cells to methylating and monochloroethylating agents in vitro and in vivo has been linked to levels of the
DNA repair protein 01-methylguanine-DNA methyttransferase (MGMT). In a clinical trial of temozolomide in advanced malignant melanoma,
the relationship between pretreatment MGMT levels in biopsies of cutaneous tumours and invotved lymph nodes and clinical response to the
drug has been studied. Among 50 evaluable patients, there were three complete responses (CR), four partial responses (PR), six with
stable disease (SD) and 37 with progressive disease (PD), with an overall response rate of 14%. In 33 patients in whom MGMT level and
clinical response could be evaluated, the tumour MGMT levels (fmol mg-1 protein) were: CR, 158 ± 119; PR, 607 ± 481; NC, 171 ± 101; PD,
185 ± 42.3. Thus, measurements of pretreatment levels of MGMT in melanoma did not predict for response to temozolomide.
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Less than one-third of patients with metastatic melanoma respond
to the best available single agent. dacarbazine (Lee et al. 1995).
Despite the development of combination regimens. the median
progression-free interval remains short and median survival is
only 6 months. It would be helpful to identify those patients
unlikely to respond to alkylating agents to spare them potentially
toxic therapy and allow them to be considered for altemative
approaches to treatment.
The Cancer Research Campaign (CRC) has identified a new
alkylating agent. temozolomide (Newlands et al. 1997). which has
actisity against melanoma comparable to that of dacarbazine
(Bleehen et al. 1995). The agent's mechanism of action depends
upon the methylation of guanine bases in DNA at the 06 position
(Margison and O'Connor. 1990). Unrepaired. the lesion can result
in chain termination. or initiate ineffective cycles of mismatch
repair leading to strand-break formation (Karran and Bignami.
1992: Griffin et al. 1994: Voigt and Topal. 1995). However. the
06-methyl adduct can be removed by the protein 06-methylgua-
nine-DNA methyltransferase (MGMT) in a stoichiometric auto-
inactivating reaction. There is evidence that MGMT expression is
a major determinant ofcellular susceptibility to methylating agent
chemotherapy: tumour cell lines or xenografts with high levels of
protein expression are more resistant to temozolomide and related
agents than those which are deficient in MGMT (Yarosh et al.
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Clinical responses to methylating. or other 06-alkylating. thera-
pies in relation to MGMT expression have been less widely
studied. Recently. an inverse correlation between clinical response
and tumour cell MGMT concentration has been reported in
leukaemia patients treated with dacarbazine (Franchi et al. 1992).
and glioma patients treated with a chloroethylnitrosourea
(Yanagisawa et al. 1996). However. in both studies numbers were
small. and the distinction between high and low MGMT levels of
expression was made retrospectively.
We have examined prospectively the relationship between
tumour MGMT concentration. measured in biopsies of cutaneous
melanoma or lymph node metastases. and response to treatment
with temozolomide in patients with advanced malignant
melanoma. Comparison between pretreatment MGMT levels in
peripheral blood mononuclear cells and tumour biopsies has also
been made in a subset ofpatients.
MATERIALS AND METHODS
Patient selection, treatment and evaluation
Patients with progressive advanced malignant melanoma were
eligible for the study. The inclusion criteria were a lesion acces-
sible for biopsy. measurable disease and adequate organ function.
A WHO performance status of3 or less was required. and previous
chemotherapy and/or radiotherapy were permitted provided that 4
weeks had elapsed from the last treatment and any toxicity had
resolved. Sixty-one patients were registered for the trial at four
centres between July 1994 and September 1996. of whom three
11991200 MR Middleton et al
Table 1 Characterstics of evaluable patients
Number (Percentage)
Total number of patients 56
Men 26 (46)
Women 30 (54)
WHO performance status
0 17 (30)
1 33 (59)
2 5 (9)
3 1 (2)
Disease sites at entry
Soft tissue 18 (32)
Visceral (not CNS) 32 (54)
CNS 8 (14)
Prior treatment
Surgery 56 (100)
Radiotherapy 12 (21)
Chemotherapya 11 (20)
Biotherapy 2 (4)
alnduding chemobiotherapy; nine of the patients had received DTIC-based
regimens.
Table 2 Characteristics of responding patients
Age/gender Disease sites Prior rapy Re se duration (days)
Complete responders
60F Soft tissue Surgery only 944 (ongoing)
58M Soft tissue Surgery onty 145
63F Soft tissue Limb perfusiona 629 (ongoing)
Partial responders
32F Visceral Surgery onty 207
48M Visceral Surgery onty 140
5OF Visceral Surgery onty 140
58F Soft tissue Surgery onty 194
aWith 5-fluorouracil.
Table 3 MGMT levets in each category of response
Number of patients MGMT (fmol mg' protein) s se.
CR 3 158 ± 119
PR 3 607±481
SD 3 171 ± 101
PD 24 185±42.3
proved ineligible (one w-ith no measurable disease. one with
inadequate hepatic function and one with inadequate renal func-
tion) and two w-ere lost to follow up. Characteristics of the
remainin, 56 patients are shown in Table 1. On the first treatment
cycle. temozolomide (supplied by the CRC Drug Formulation
Unit. University of Strathclyde. UK) was given at 150 mg m-'
daily by mouth for 5 days. If myelotoxicity was grade 0 or 1. the
dose was increased to 200 mg m-2 day-' for subsequent cycles.
Cycles were repeated every 28 days.
Responses were determined according to WHO cnrteria (1979).
Patients had to receive at least two cycles of treatment so that
response could be compared with the tumour biopsy MGMT level.
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Figure 1 Pretreatment tunour biopsy MGMT concentration in comparison
withdinical response
Those who were unable to complete two cycles of treatment were
assessed for toxicity. according to CTC criteria (Miller et al.
1981). and response only. The trial was approsved by the appro-
priate local ethical review committees.
Tumour biopsy MGMT determination
Biopsies of cutaneous melanoma or lymph node metastases wvere
taken before the treatment started. and extracts prepared for
measurement of MGMT expression. Levels in tumour biopsy
samples were determined in three ofthe fourparticipating, centres.
according to the methods ofLee et al (1991) orMajor et al (1991).
These methods quantify MGMT activity by measuring the transfer
of tritiated methyl groups from DNA to the protein fraction.
containing MGMT. in cell extracts. A number of samples were
analysed at all three laboratories to ensure consistency ofmeasure-
ment. In a subset of patients. peripheral blood was collected
immediately before treatment. mononuclear cells separated by
Ficoll-Hypaque density centrifugation and analysed as above.
RESULTS
Treatment was well tolerated: only one patient was withdrawn
from the study because ofdrug toxicity. suffering prolonged grade
IV thrombocytopenia Lymphocytopenia was common (occurmng
in 85% of patients). but there were only eight (4% of cycles) and
nine (5%) reports of grade 3 or higher neutropenia and thrombo-
cytopenia. respectively. in 189 cycles of treatment. The most
frequent non-haematological toxicities were nausea (in 60% of
patients). vomiting (45%). constipation (43%). diarrhoea (21%)
and stomatitis (12%). Five patients could not be assessed because
they died before completing a cycle of treatment. All these deaths
were due to progressive malignant melanoma except one. The
exception was a patient who died of pneumonia 21 days into the
first cycle of treatment. which was not obviously related to temo-
zolomide use.
Clinical response was not evaluable in one patient. In the
remaining 50 patients. there were three (6%) complete responses
(CR). four (8%) partial responses (PR). six (12%) patients with
stable disease (SD) and 37 (74%) with progressive disease (PD).
giving an overall response rate of 14%. The characteristics of the
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responding patients are summarized in Table 2. Median time to
progression for all evaluable patients w-as 57.5 days and median
survival 159.5 days.
In 17 of the 50 evaluable patients. response could not be
assessed aaainst tumour biopsy MGMT level: seven had earlv
progression and ten had biopsies which were inadequate for
assessing the protein level. Results from the 33 patients in whom
both response and MGMT expression could be examined are
presented in Table 3 and Figure 1. There was no significant differ-
ence in pretreatment MGMT levels between those who responded
to temozolomide and those who did not (P = 0.95: Mann-Whitney
test). MGMT levels did not correlate w-ith an individual's time to
progression nor overall survival. In ten patients. there was no
linear (r = 0.045. P = NS) or rank (r = 0.097. P = 0.40) relationship
bettween pretreatment peripheral blood mononuclear cell and
tumour biopsy MGMT levels.
DISCUSSION
The overall response rate of 14%7c observed in the present study is
lower than that seen in the earlier CRC phase II study oftemozolo-
mide in advanced malignant melanoma (Bleehen et al. 1995).
However. patients in the earlier study were chemotherapy naive
and had a better median performance status at the start of temo-
zolomide therapy. and only one patient had CNS disease
(compared with eight in this study). No patient in the current trial
who had received previous systemic chemotherapy responded to
temozolomide. The majority of the regimens given before temo-
zolomide included dacarbazine. which shares the active inter-
mediate 5-(3-methyl- 1-triazenvl)imidazole4-carboxamide with
temozolomide. so that cross-resistance is not unexpected.
However. there was no difference in the mean MGMT levels of
patients who had received prior chemotherapy and those who had
not (data not shown). The toxicities seen in this study are similar to
those in the previous melanoma trial and other phase II studies
(Bleehen et al. 1995: Bower et al. 1997).
These results show no relationship bet-een averaged tumour
MGMT activity and response to temozolomide chemotherapy.
Although there are a number ofother variables to take into account
(such as drug, absorption. metabolism and penetration to tumour
sites). this is surprising in the face of the large body of preclinical
in vitro and xenograft evidence for such a correlation. However.
the measure of tumour MGMT used in this investigation may not
have been representative of the tumour as a whole. Thus. it may
not be reasonable to view the tumour as a single entity with regaard
to MGMI activitv. given the heterogeneity of expression found in
immunohistochemical studies (Lee et al. 1992) or the different
levels of expression found in multiple skin metastases biopsied in
the same patient (Eghvazi et al. 1995). Although MGMI was
measured in samples pared of non-tumour tissue visible to the
naked eye. the activitv recorded represents the mean for all the cell
types present. notjust tumour.
The relationship between MGMT and tumour sensitivity to
temozolomide. if one exists. is unlikelv to be straiahtforward:
w-here methvlated DNA is not repaired other factors. such as
mismatch repair and p53 status. will influence whether the cell
dies. Cell lines deficient in mismatch repair tolerate aLkylation
damnae (Branch et al. 1993: Kat et al. 1993). and it has recently
been suggested that this deficiency overrides MGMT in conferrinc
resistance to temozolomide (Liu et al. 1996: Wedge et al. 1996).
Results should soon be available from clinical trials w-ith
06-benzylguanine. an MGMT inacti-ator. in combination with
06-alkylating agents. The ability of this. or similar inactivators. to
enhance the efficacy of alkylating agent chemotherapy will help
determine the functional role that MGMT plays in tumour resis-
tance to these therapies. Meanwhile. further work is needed in
malignant melanoma to determine tumour-specific MGMT levels
via immunohistochemistrv. and in the investigation of alternative
mechanisms ofresistance to 06-alky-lators such as mismatch repair
deficiency.
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